pyrroles has been researched along with Hyperlipoproteinemia Type II in 116 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (15.52) | 18.2507 |
| 2000's | 81 (69.83) | 29.6817 |
| 2010's | 17 (14.66) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jannes, CE; Krieger, JE; Morgan, AC; Pereira, AC; Santos, PC; Santos, RD; Turolla, L | 1 |
| Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y | 1 |
| Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Jannes, CE; Krieger, JE; Morgan, AC; Pereira, AC; Santos, PC; Santos, RD | 1 |
| Drogari, E; Elens, L; Manolopoulos, VG; Mollaki, V; Ragia, G; Van Schaik, RH | 1 |
| Ahmed, MH; Elmadhoun, WM; Hassan, AT; Husain, NE | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Basart, DC; Defesche, JC; Heeringa, J; Kastelein, JJ; Lansberg, PJ; Liem, AH; Oosterveer, DM; Sijbrands, EJ; Versmissen, J; Witteman, JC; Yazdanpanah, M | 1 |
| Catalano, G; Chapman, MJ; Fournier, N; Frisdal, E; Guerin, M; Julia, Z; Le Goff, W; Vedie, B | 1 |
| Jin, H; Li, ZG; Xu, ZY; Yao, F | 1 |
| Davignon, J; Dubuc, G | 1 |
| Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL | 1 |
| Bláha, M; Bláha, V; Lánská, M; Malý, J; Nováková, L; Solich, P; Solichová, D; Vlcková, H | 1 |
| Gandelman, K; Glue, P; Jones, J; LaBadie, R; Laskey, R; Ose, L | 1 |
| Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Nemati, MH | 1 |
| Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Ieva, R; Montrone, D; Ruggiero, A | 1 |
| Du, Y; Gasparino, E; Gutierrez, M; Kranz, T; Lisbon, E; Logan, D; Mellis, S; Smith, WB; Stahl, N; Stein, EA; Swergold, GD; Webb, C; Wu, R; Yancopoulos, GD | 1 |
| Kalil Filho, R; Kowatsch, I; Lario, FC; Mathias, W; Miname, MH; Ramires, JA; Santos, RD; Sbano, JC; Tsutsui, JM | 1 |
| El-Tahtawy, A; Gandelman, K; Gastonguay, MR; Jen, F; Knebel, W; Malhotra, B | 1 |
| Derfler, K; Goldammer, A; Heinz, G; Hörl, WH; Jansen, M; Stulnig, T; Wiltschnig, S | 1 |
| Chapman, MJ; Dupuis, R; Egger, P; Guerin, M; Le Goff, W; Soudant, C | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Klikczynska, K; Koter, M | 1 |
| Knight, BL; Naoumova, RP; O'Neill, FH; Patel, DD; Thompson, GR | 1 |
| Sinzinger, H | 1 |
| Alvarez, E; Castaño, G; Fernández, L; Illnait, J; Lezcay, M; Mas, R; Mesa, M | 1 |
| Aukrust, P; Frøland, SS; Gullestad, L; Kastelein, JJ; Pedersen, TR; Semb, AG; Smilde, T; Stalenhoef, AF; Tripp, MD; Ueland, T; van Wissen, S; Waehre, T | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Baldi, S; Blandizzi, C; Del Tacca, M; L'Abbate, A; Lubrano, V; Natali, A; Palombo, C; Vassalle, C | 1 |
| Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Larivière, M; Pirro, M | 1 |
| Amano, Y; Imura, Y; Ishikawa, E; Nishimoto, T; Sugiyama, Y; Tozawa, Ri | 1 |
| de Boo, T; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Furberg, CD; Kritz, H; Sinzinger, H | 1 |
| Annuar, R; Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K | 1 |
| Amsellem, S; Atassi, M; Benlian, P; Beucler, I; Bruckert, E; Gonbert, S; Khallouf, O; Sposito, AC; Turpin, G | 1 |
| Kajinami, K; Kanayama, S; Kanemitsu, S; Matsui, S; Okubo, S; Sato, R; Takekoshi, N; Yamashita, N | 1 |
| Aligisheeva, ZA; At'kov, OIu; Balakhonova, TV; Kukharchuk, VV; Pogorelova, OA; Susekov, AV; Titov, VN | 1 |
| Diggle, PJ; Miller, E; Southworth, H; Stein, EA; Strutt, K | 1 |
| Gross, B; Hättenschwiler, A; Schulthess, G; Widmer, Ch | 1 |
| Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ | 1 |
| Angelin, B; Berglund, L; Borgström, B; Eggertsen, G; Ericsson, S; Eriksson, M; Lind, S; Olivecrona, H; Rudling, M | 1 |
| de Groot, E; Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Wissen, S | 1 |
| de Grooth, GJ; Fruchart, JC; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Smilde, TJ; Stalenhoef, AF; Van Wissen, S; Zwinderman, AH | 1 |
| Cording, SA; Newnham, HH; Rando, LP | 1 |
| Azuma, N | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Tits, LJ; van Wissen, S | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Higashikata, T; Inazu, A; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Nohara, A | 1 |
| Bairaktari, E; Cariolou, M; Elisaf, M; Ganotakis, M; Miltiadous, G; Xenophontos, S | 1 |
| Ascaso, JF; Carmena, R; Chaves, FJ; Civera, M; García-García, AB; González, C; González-Albert, V; Martín de Llano, JJ; Real, JT | 1 |
| de Graaf, J; Lemmers, HL; Stalenhoef, AF; van Himbergen, TM; van Tits, LJ | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Kostka, B; Marczyk, I; Michalska, M; Sikora, J | 1 |
| de Graaf, J; Himbergen, TM; Roest, M; Stalenhoef, AF; van Tits, LJ; Voorbij, HA | 1 |
| Fusegawa, Y; Handa, S; Homma, Y; Oguma, T; Ozawa, H; Shiina, Y; Tanabe, T | 1 |
| de Bont, N; Demacker, PN; Hijmans, A; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Abruzzese, G; Avellone, G; Campisi, D; De Simone, R; Di Garbo, V; Licata, G; Raneli, G | 1 |
| Ishii, T; Kaneki, M; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 1 |
| Cariolou, M; Christidis, DS; Elisaf, MS; Ganotakis, ES; Kakafika, AI; Liberopoulos, EN; Mikhailidis, DP; Miltiadous, GA | 1 |
| Cía, M; Martínez, M; Otermin, I; Pereda, A; Rivero, M | 1 |
| Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Hashemi, MJ; Hekmat, M; Kouhi, A; Mojtahedzadeh, S; Naderi, N; Nobahar, R; Rafeiyian, S | 1 |
| Blasetto, J; Marais, AD; Palmer, M; Raal, FJ; Rader, DJ; Stein, EA; Wilpshaar, W | 1 |
| Frøbert, O; Holmager, P; Jensen, KM; Schmidt, EB; Simonsen, U | 1 |
| Chapman, MJ; Duchene, E; Guerin, M; Julia, Z; Le Goff, W; Nguyen, T; Shear, CL; Thuren, T | 1 |
| Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Mori, M; Nohara, A; Tada, H; Tsuchida, M; Yamagishi, M | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Alonso, R; Fernández de Bobadilla, J; Lázaro, P; Mata, N; Mata, P; Méndez, I | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Abu-Muhana, O; Dunn, S; Naoumova, RP; Neuwirth, C; Rallidis, L; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J | 1 |
| Firth, JC; Marais, AD; Naoumova, RP; Neuwirth, CK; Penny, C; Thompson, GR | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 2 |
| de Bont, N; Demacker, PN; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Hoogerbrugge, N | 1 |
| Bandinelli, S; Bertolotto, A; Lo Faro, A; Navalesi, R; Penno, G; Ruocco, L | 1 |
| Axelson, M; Dunn, S; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Taylor, GW; Thompson, GR | 1 |
| Dominiczak, MH; Murphy, MJ | 1 |
| Genest, J; Lavoie, MA | 1 |
| Jonkers, GH | 1 |
| Hoogerbrugge, N; Jansen, H | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Mancini, M; Montefusco, S; Pauciullo, P; Piliego, T; Postiglione, A | 1 |
| de Man, FH; Mohrschladt, MF; Smelt, AH; Stoeken, DJ; Sturk, A; Westendorp, RG; Weverling-Rijnsburger, AW | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 3 |
| Banyai, S; Derfler, K; Goldammer, A; Hörl, WH; Jansen, M; Rohac, M; Schmaldienst, S | 1 |
| Black, DM; Firth, JC; Heinonen, TM; Illingworth, DR; Kotze, MJ; Marais, AD; Pappu, AS; Pilcher, GJ; Raal, FJ | 1 |
| Choy, PC; Dembinski, T; Hatch, G; Kroeger, EA; McMaster, J; Mymin, D; Zhu, Q | 1 |
| Donner, MG; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Banyai, S; Derfler, K; Heinz, G; Hörl, WH; Jansen, M; Schmaldienst, S; Stulnig, TM | 1 |
| Endo, M; Harada-Shiba, M; Hori, H; Imai, T; Ito, T; Kato, H; Kawaguchi, A; Kubo, H; Mikami, Y; Oi, K; Sakai, S; Sato, I; Suzuki, Y; Yamamoto, A | 1 |
| Mohrschladt, MF; Smelt, AH; Westendorp, RG | 1 |
| Elisaf, M; Miltiadous, G; Tsimihodimos, V | 1 |
| Bourbon, M; Knight, BL; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Patel, DD; Soutar, AK; Taylor, GW; Thompson, GR | 1 |
| Bo, M; Fabris, F; Fiandra, U; Mercadante, G; Nicolello, MT; Piliego, T | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Crook, MA; Mikhalidis, DP; Reynolds, TM; Wierzbicki, AS | 1 |
| Durrington, PN | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S; Wollersheim, H | 1 |
| Keller, U; Mirsaidi, R; Miserez, AR | 1 |
| Harada-Shiba, M; Kawaguchi, A; Tsushima, M; Yamamoto, A | 1 |
| Alt, E; Banyai, M; Banyai, S; Derfler, K; Falger, J; Jansen, M; Koppensteiner, R | 1 |
| Athyros, VG; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Jouanel, P; Malpuech, G; Meyer, M; Palcoux, JB; Vanlieferinghen, P | 1 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Chapman, MJ; Dupuis, R; Egger, P; Guerin, M; Le Goff, W; Soudant, C; van Tol, A | 1 |
5 review(s) available for pyrroles and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL | 2014 |
Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): what are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Approval; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Insulin Resistance; Pyrroles | 2015 |
[LDL adsorption for therapy of hyperlipidemia].
Topics: Adsorption; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Hemoperfusion; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrroles | 2004 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Apheresis technology for prevention and regression of atherosclerosis.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Plasmapheresis; Pyrroles; Treatment Outcome | 2001 |
54 trial(s) available for pyrroles and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL2; Lipoproteins, HDL3; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrroles; Quinolines; Scavenger Receptors, Class B; Time Factors; Treatment Outcome | 2009 |
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography | 2010 |
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Tolerance; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pyrroles; Retrospective Studies; Treatment Outcome | 2011 |
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Injections, Intravenous; Injections, Subcutaneous; Least-Squares Analysis; Lipoproteins; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; Serine Endopeptidases | 2012 |
Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Myocardial Perfusion Imaging; Pyrroles; Treatment Outcome | 2013 |
Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults.
Topics: Adolescent; Adult; Atorvastatin; Child; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Models, Biological; Pyrroles | 2013 |
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Topics: Adult; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2002 |
Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Interleukin-10; Interleukin-12; Interleukin-12 Subunit p35; Leukocytes, Mononuclear; Lipids; Male; Mevalonic Acid; Middle Aged; Protein Subunits; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Single-Blind Method | 2003 |
Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Alcohols; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pyrroles; Single-Blind Method; Treatment Outcome | 2003 |
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Adult; Atorvastatin; Biomarkers; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2003 |
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Vascular Cell Adhesion Molecule-1; Vasodilation | 2003 |
Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Atorvastatin; Blood Component Removal; Child; Cholesterol, HDL; Female; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Phenotype; Pyrroles; Receptors, LDL | 2003 |
Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Bone and Bones; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Osteogenesis; Pyrroles; Vitamin D | 2003 |
[Atorvastatin in the treatment of patients with hereditary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Least-Squares Analysis; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Treatment Outcome | 2003 |
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome | 2003 |
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2003 |
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Analysis of Variance; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probability; Prognosis; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2004 |
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemi
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Media; Ultrasonography | 2004 |
Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH).
Topics: Anion Exchange Resins; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Epichlorohydrin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Imidazoles; Japan; Male; Middle Aged; Pyrroles; Resins, Synthetic | 2005 |
[The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II].
Topics: Aged; Antithrombin III; Atorvastatin; Factor X; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Carboxylic Ester Hydrolases; Cholesterol, HDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Safety; Triglycerides | 2006 |
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2007 |
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography | 2007 |
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2008 |
Effect of acute changes in oxygen tension on flow-mediated dilation. Relation to cardivascular risk.
Topics: Administration, Inhalation; Adult; Atorvastatin; Brachial Artery; Cardiovascular Diseases; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperoxia; Hypoxia; Lipoproteins; Male; Middle Aged; Nitroglycerin; Oxygen; Pyrroles; Regional Blood Flow; Research Design; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography; Vasoconstriction; Vasodilation; Vasodilator Agents | 2008 |
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Chylomicrons; Dietary Fats; Dietary Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Quinolines | 2008 |
Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coenzymes; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides; Ubiquinone | 2008 |
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Creatinine; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Pyrroles | 1997 |
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Uric Acid | 1997 |
Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Enzyme Inhibitors; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Kinetics; Lipids; Lipoproteins, LDL; Male; Mevalonic Acid; Pyrroles | 1997 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD11 Antigens; Cohort Studies; Cytokines; Double-Blind Method; Heptanoic Acids; Heterozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipopolysaccharide Receptors; Lipopolysaccharides; Mice; Monocytes; Pyrroles; Simvastatin | 1998 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Treatment Outcome | 1999 |
Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway.
Topics: Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Biomarkers; Cholestenones; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Jejunoileal Bypass; Lipids; Lipoproteins; Male; Mevalonic Acid; Middle Aged; Pyrroles; Up-Regulation | 1999 |
Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Sex Distribution; Treatment Outcome | 1999 |
Effects of atorvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Pyrroles; Treatment Outcome | 1999 |
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Reference Values | 2000 |
Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 1999 |
Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; DNA; DNA Mutational Analysis; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Mutation; Polymorphism, Single-Stranded Conformational; Prognosis; Pyrroles; Receptors, LDL | 2000 |
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hemorheology; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Plasma Volume; Pyrroles; Simvastatin | 2000 |
Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.
Topics: Adsorption; Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cross-Over Studies; Dextran Sulfate; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles | 2000 |
High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Regression Analysis; Simvastatin; Triglycerides | 2000 |
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2001 |
Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestenones; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Mutation; Pyrroles; Receptors, LDL; RNA, Messenger | 2001 |
Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2001 |
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Pyrroles; Simvastatin; Tunica Intima | 2001 |
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Female; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrroles | 2002 |
57 other study(ies) available for pyrroles and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Brazil; Cholesterol, LDL; Ezetimibe; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Pyrroles; Receptors, LDL | 2014 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Base Sequence; Brazil; Cholesterol; DNA Primers; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Ubiquitin-Protein Ligases | 2014 |
POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.
Topics: Adolescent; Alleles; Atorvastatin; Child; Female; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins, LDL; Male; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Pyrroles; Receptors, LDL | 2014 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
Topics: Adult; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body in familial hypercholesterolemia.
Topics: Aortic Valve Stenosis; Atorvastatin; Blood Component Removal; Female; Heart Valve Prosthesis Implantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Mitral Valve Insufficiency; Pyrroles; Treatment Outcome; Xanthomatosis; Young Adult | 2009 |
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; Case-Control Studies; Ezetimibe; Female; Genetic Variation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; RNA, Messenger; Serine Endopeptidases; Young Adult | 2009 |
Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Hemofiltration; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric; Tandem Mass Spectrometry | 2011 |
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia.
Topics: Angioplasty; Atorvastatin; Carotid Stenosis; Disease Progression; Genetic Predisposition to Disease; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver Transplantation; Phenotype; Pyrroles; Radiography; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Treatment Refusal | 2011 |
Early onset of coronary heart disease in a young woman with familial hypercholesterolemia: coronary findings and effect of short term treatment with high dose atorvastatin.
Topics: Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Radiography; Time Factors; Treatment Outcome; Young Adult | 2012 |
Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2002 |
Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Chylomicrons; Fasting; Food; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipids; Male; Membrane Fluidity; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2002 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
The effect of lipoproteins on endothelial nitric oxide synthase is modulated by lipoperoxides.
Topics: Adult; Anticholesteremic Agents; Ascorbic Acid; Atorvastatin; Cells, Cultured; Cholesterol, LDL; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Synergism; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipid Peroxides; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Nitrates; Nitric Oxide Synthase; Nitrites; Pyrroles | 2003 |
Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrophoresis, Polyacrylamide Gel; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Particle Size; Probability; Prospective Studies; Pyrroles; Treatment Outcome | 2003 |
Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Disease Models, Animal; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mice; Mice, Knockout; Oxazepines; Piperidines; Pyrroles; Rabbits; Receptors, LDL; Simvastatin; Species Specificity; Time Factors; Triglycerides | 2003 |
Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.
Topics: Adult; Albuminuria; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Case-Control Studies; Cholesterol, LDL; Creatinine; Female; Heptanoic Acids; Homeostasis; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles | 2003 |
["Gout tophi" and heart disease in the family].
Topics: Adult; Arcus Senilis; Atorvastatin; Cholesterol; Cholesterol, HDL; Diagnosis, Differential; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Heart Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Time Factors; Xanthomatosis | 2003 |
Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans.
Topics: Adult; Atorvastatin; Bile Acids and Salts; Child; Cholesterol, LDL; Colestipol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Human Growth Hormone; Humans; Hyperlipoproteinemia Type II; Hypopituitarism; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2004 |
Successful reintroduction of statin therapy after myositis: was there another cause?
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypothyroidism; Male; Myositis; Pyrroles; Simvastatin | 2004 |
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2005 |
Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
Topics: Apolipoproteins E; Atorvastatin; Body Mass Index; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Female; Genotype; Glycoproteins; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins, LDL; Male; Multivariate Analysis; Mutation; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Receptors, LDL | 2005 |
Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
Topics: Alleles; Apolipoproteins E; Atorvastatin; Body Mass Index; Carrier Proteins; Cholesterol; Cholesterol, LDL; DNA; Fasting; Female; Genetic Variation; Genotype; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Male; Mutation; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Pyrroles; Sex Factors; Triglycerides | 2005 |
Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2006 |
A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.
Topics: Achilles Tendon; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Component Removal; Coronary Vessels; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Middle Aged; Pedigree; Pyrroles; Radiography; Xanthomatosis | 2005 |
LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Genetic Carrier Screening; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Platelets; C-Reactive Protein; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Patient Compliance; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2006 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
[Musculoskeletal adverse effects of levofloxacin].
Topics: Anti-Bacterial Agents; Arthralgia; Arthritis; Arthritis, Infectious; Arthroplasty, Replacement, Knee; Atorvastatin; Combined Modality Therapy; Debridement; Diagnosis, Differential; Doxycycline; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Levofloxacin; Middle Aged; Ofloxacin; Postoperative Complications; Prosthesis-Related Infections; Pyrroles; Recurrence; Reoperation; Rifampin; Thyroiditis, Autoimmune; Thyroxine; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Supravalvular and valvular aortic stenosis in heterozygous familial hypercholesterolemia.
Topics: Adolescent; Aortic Stenosis, Supravalvular; Aortic Valve Stenosis; Atorvastatin; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Niacin; Pyrroles | 2007 |
[Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Models, Economic; Pyrroles | 2008 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
[Lowering cholesterol. New concepts with atorvastatin].
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Pyrroles; Treatment Outcome | 1997 |
Effect of atorvastatin on plasma fibrinogen.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles | 1998 |
Efficacy of statin therapy: possible effect of phenytoin.
Topics: Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Epilepsy; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenytoin; Pyrroles; Simvastatin | 1999 |
Images in clinical medicine. Homozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Elbow; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Pyrroles | 1999 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Equipment Design; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins, LDL; Long-Term Care; Male; Middle Aged; Plasmapheresis; Pyrroles; Treatment Outcome | 2000 |
Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Diet Therapy; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lysophosphatidylcholines; Muscle, Smooth, Vascular; Oxidation-Reduction; Phospholipids; Pyrroles | 2000 |
The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Component Removal; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoprotein(a); Lipoproteins; Lipoproteins, LDL; Lymphocytes; Male; Mevalonic Acid; Middle Aged; Pyrroles; Receptors, LDL | 2000 |
Endotoxin-lipoprotein hypothesis.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Interleukin-10; Lipopolysaccharides; Pyrroles; Tumor Necrosis Factor-alpha | 2000 |
Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2000 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Measurement of atherosclerosis progression.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2001 |
Rigorous detection and vigorous treatment of familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Ultrasonography | 2001 |
Development of tachyphylaxis on statin treatment.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrroles; Research Design; Simvastatin; Tachyphylaxis | 2001 |
Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Plasmapheresis; Probability; Prospective Studies; Pyrroles; Rheology; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2001 |
[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2001 |
Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Pyrroles | 2002 |
Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Atorvastatin; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Long-Term Care; Male; Prognosis; Prospective Studies; Pyrroles; Treatment Outcome | 2002 |